Thermo Fisher Q3 2026: The Lab Recovery Is Real

Podcast: Exponential Learning · The Team

Opublikowano: 2026-10-22

Thermo Fisher beat and raised: revenue +9% to $12.14B with 6% organic growth, adjusted EPS +15% to $6.68, and FY26 guidance lifted on revenue, EPS and free cash flow. Pharma Services and clinical research led, China grew low double digits, and biotech funding is improving — the life-sciences spending recovery is real. The honest footnotes: about $0.15 of the EPS beat was a one-time tariff refund, Life Sciences Solutions grew just 1% organically, Q4 organic growth is guided at 4% on Pharma Services timing, and after a ~35% six-month run the stock sits ~1% below its 52-week high with the consensus target still below the price. Next catalyst: 2027 guidance on Fe...